Brexpa-1 Tablet Tablet

About Brexpa-1 Tablet

Brexpa-1 Tablet is made by Renata PLC. and contains brexpiprazole 1 mg in tablet form. It is an atypical antipsychotic used in the treatment of schizophrenia and as an add-on therapy for major depressive disorder.

There are 2 brands of Brexpiprazole listed in Bangladesh.

What is Brexpa-1 Tablet?

Brexpa-1 Tablet is a prescription medicine manufactured by Renata PLC. It contains brexpiprazole 1 mg, an atypical antipsychotic. It is used to treat schizophrenia and, in combination with antidepressants, to treat major depressive disorder. Brexpiprazole works by adjusting the activity of certain chemical messengers in the brain, such as serotonin and dopamine, although the exact way it works is not fully understood. This medicine should only be taken under the guidance of a doctor, who will decide the dose and course of treatment based on the individual's condition.

Uses of Brexpa-1 Tablet

Brexpa-1 Tablet is used for two main conditions: schizophrenia and major depressive disorder. In major depressive disorder, it is used as an add-on to antidepressant medication. It is not a stand-alone treatment for depression. The doctor will determine if this medicine is suitable for a particular patient and will decide the appropriate dose and duration of treatment.

How to use Brexpa-1 Tablet

Brexpa-1 Tablet is taken by mouth, with or without food. The dose and how often it is taken are decided by the doctor, who will consider the patient's condition and response to treatment. Do not change the dose or stop taking this medicine without consulting the doctor. If a dose is missed, ask the doctor or pharmacist for advice. The tablet should be swallowed whole with water.

Side effects of Brexpa-1 Tablet

Side effects can occur with Brexpa-1 Tablet. Contact the doctor immediately if you notice signs such as high fever, stiff muscles, confusion, sweating, irregular heartbeat, unusual movements of the face or tongue, or unusual urges such as gambling. Also seek medical advice if you experience dizziness, drowsiness, weight gain, or changes in blood sugar. Report any side effect to the doctor or pharmacist.

Safety and precautions

Before taking Brexpa-1 Tablet, tell the doctor about any medical conditions, especially dementia-related psychosis in elderly patients, heart problems, diabetes, or low white blood cell counts. The doctor will decide if this medicine is appropriate. For pregnant or breastfeeding women, the doctor should be consulted to weigh the benefits and risks. Do not take this medicine if you are allergic to brexpiprazole or any of its ingredients. Always inform the doctor about all medicines you are taking.

Frequently asked questions

How should Brexpa-1 Tablet be taken?

Brexpa-1 Tablet is taken by mouth, with or without food. The doctor decides the dose, how often to take it, and how long to continue. Do not change the dose or stop the medicine without the doctor's advice. Follow the doctor's instructions exactly.

What does the generic name brexpiprazole mean?

Brexpiprazole is the generic name of the active ingredient. It is an atypical antipsychotic. The name does not describe the condition it treats; it is simply the chemical name used for the medicine. Your doctor or pharmacist can explain more about the medicine.

What side effects should I watch for and when should I call the doctor?

Call the doctor right away if you have high fever, stiff muscles, confusion, sweating, irregular heartbeat, unusual movements of the face or tongue, or unusual urges like gambling. Also report dizziness, drowsiness, weight gain, or any other side effect to the doctor or pharmacist.

Can Brexpa-1 Tablet be used during pregnancy or breastfeeding?

There is a pregnancy exposure registry for brexpiprazole. It is not known if brexpiprazole passes into human milk. The doctor will decide if this medicine is suitable during pregnancy or breastfeeding, weighing the benefits and risks. Always consult the doctor before use.

Indications

Brexpiprazole is an atypical antipsychotic indicated for:
  • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
  • Treatment of schizophrenia

Pharmacology

The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.

Dosage & Administration

Adjunctive Treatment of Major Depressive Disorder: The recommended starting dosage for Brexpiprazole as adjunctive treatment is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment.

Treatment of Schizophrenia: The recommended starting dosage for Brexpiprazole is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Brexpiprazole dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 4 mg.

Contraindications

Brexpiprazole is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis.

Pregnancy & Lactation

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Brexpiprazole during pregnancy.

Lactation studies have not been conducted to assess the presence of brexpiprazole in human milk, the effects of brexpiprazole on the breastfed infant, or the effects of brexpiprazole on milk production. Brexpiprazole is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Brexpiprazole and any potential adverse effects on the breastfed infant from Brexpiprazole or from the underlying maternal condition.

Precautions & Warnings

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-
  • Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack)
  • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring
  • Tardive Dyskinesia: Discontinue if clinically appropriate
  • Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain
  • Pathological Gambling and Other Compulsive Behaviors: Consider dose reduction or discontinuation
  • Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Brexpiprazole if a clinically significant decline in WBC occurs in absence of other causative factors
  • Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope
  • Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold

Storage Conditions

Store Brexpiprazole tablets at 20°C to 25°C; excursions permitted to 15°C to 30°C

Alternative brands of Brexpiprazole

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.